Addex Therapeutics (ADXN) Competitors $8.75 -0.25 (-2.78%) As of 12:56 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. CGTX, KALA, BDRX, AKTX, TELO, COEP, HYPD, OKUR, MAAQ, and KZRShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Cognition Therapeutics (CGTX), KALA BIO (KALA), Biodexa Pharmaceuticals (BDRX), Akari Therapeutics (AKTX), Telomir Pharmaceuticals (TELO), Coeptis Therapeutics (COEP), Hyperion DeFi (HYPD), OnKure Therapeutics (OKUR), Mana Capital Acquisition (MAAQ), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Cognition Therapeutics KALA BIO Biodexa Pharmaceuticals Akari Therapeutics Telomir Pharmaceuticals Coeptis Therapeutics Hyperion DeFi OnKure Therapeutics Mana Capital Acquisition Kezar Life Sciences Addex Therapeutics (NASDAQ:ADXN) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk. Do analysts recommend ADXN or CGTX? Addex Therapeutics currently has a consensus target price of $30.00, indicating a potential upside of 242.86%. Cognition Therapeutics has a consensus target price of $2.83, indicating a potential upside of 366.78%. Given Cognition Therapeutics' higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has better valuation and earnings, ADXN or CGTX? Addex Therapeutics has higher revenue and earnings than Cognition Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$460K20.16$8.02M-$0.34-25.74Cognition TherapeuticsN/AN/A-$33.97M-$0.74-0.82 Is ADXN or CGTX more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to Cognition Therapeutics' net margin of 0.00%. Addex Therapeutics' return on equity of -54.27% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Addex Therapeutics3,584.49% -54.27% -49.15% Cognition Therapeutics N/A -194.42%-115.14% Do institutionals and insiders have more ownership in ADXN or CGTX? 16.1% of Addex Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 15.0% of Addex Therapeutics shares are owned by insiders. Comparatively, 14.4% of Cognition Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer ADXN or CGTX? In the previous week, Cognition Therapeutics had 11 more articles in the media than Addex Therapeutics. MarketBeat recorded 12 mentions for Cognition Therapeutics and 1 mentions for Addex Therapeutics. Addex Therapeutics' average media sentiment score of 1.87 beat Cognition Therapeutics' score of 0.78 indicating that Addex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Addex Therapeutics Very Positive Cognition Therapeutics Positive Which has more risk and volatility, ADXN or CGTX? Addex Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Cognition Therapeutics has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. SummaryAddex Therapeutics beats Cognition Therapeutics on 9 of the 15 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.28M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-25.749.1728.6319.67Price / Sales20.16745.64439.23185.66Price / CashN/A164.3436.0257.93Price / Book0.844.698.185.64Net Income$8.02M$30.99M$3.23B$257.73M7 Day Performance-5.81%1.06%-0.20%0.21%1 Month Performance9.36%8.23%5.43%8.47%1 Year Performance5.93%-5.71%26.39%13.93% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.5147 of 5 stars$8.75-2.8%$30.00+242.9%+8.5%$9.28M$460K-25.7430Positive NewsGap DownCGTXCognition Therapeutics2.9157 of 5 stars$0.61+6.6%$2.83+368.3%-70.4%$37.51MN/A-0.8220News CoverageGap UpKALAKALA BIO3.8826 of 5 stars$5.70-2.6%$13.00+128.1%-28.1%$36.77M$3.89M-0.6930BDRXBiodexa Pharmaceuticals0.2317 of 5 stars$0.98+12.1%N/AN/A$35.81M$470K0.0020Gap DownHigh Trading VolumeAKTXAkari Therapeutics0.7024 of 5 stars$1.11-1.7%N/A-70.9%$35.75MN/A0.009TELOTelomir Pharmaceuticals3.545 of 5 stars$1.17+0.9%$15.00+1,182.1%-72.7%$34.82MN/A-2.791Positive NewsCOEPCoeptis Therapeutics0.5043 of 5 stars$9.90+4.5%N/A+62.4%$34.79M$62.87K-1.712News CoverageHYPDHyperion DeFi0.6141 of 5 stars$12.03-9.1%$2.00-83.4%-84.9%$34.65M$60K-0.2140OKUROnKure Therapeutics3.5906 of 5 stars$2.50flat$32.33+1,193.3%N/A$33.78MN/A-0.48N/APositive NewsMAAQMana Capital AcquisitionN/A$4.15-3.3%N/A+657.3%$33.72MN/A0.001KZRKezar Life Sciences4.1863 of 5 stars$4.58+1.6%$39.50+762.4%-27.2%$33.48M$7M-0.4260News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Cognition Therapeutics Alternatives KALA BIO Alternatives Biodexa Pharmaceuticals Alternatives Akari Therapeutics Alternatives Telomir Pharmaceuticals Alternatives Coeptis Therapeutics Alternatives Hyperion DeFi Alternatives OnKure Therapeutics Alternatives Mana Capital Acquisition Alternatives Kezar Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
